Trial reportScientific reports2026
Randomized study of the efficacy, safety, and pharmacokinetics of SPR720 for the treatment of Mycobacterium avium complex pulmonary disease.
Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05496374 (A Randomized, Investigator-Blinded, Placebo-Controlled, Multicenter, Phase 2, Dose-Ranging Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Patients With Mycobacterium Avium Complex), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Investigator-Blinded, Placebo-Controlled, Multicenter, Phase 2, Dose-Ranging Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SPR720 is an aminobenzimidazole that is converted rapidly in vivo to the active moiety SPR719, which inhibits in mycobacteria the ATPase activity of DNA gyrase B. The efficacy, safety, and pharmacokinetics of orally administered SPR720 were evaluated in patients with nontuberculous mycobacterial pulmonary disease (NTM-PD). Twenty-two patients meeting criteria for nodular-bronchiectatic NTM-PD were randomly assigned in a 1:1:1 ratio to placebo, SPR720 500 mg once daily (QD), or SPR720 1000 mg QD for 56 days, and three patients received open-label treatment with SPR720 1000 mg QD or SPR720 500 mg twice daily. For the primary efficacy endpoints, observed weekly sputum log10 CFU/mL and time to positivity, no difference was observed among treatment groups with no dose response between SPR720 500 mg QD and 1000 mg QD. Mycobacterial suppression was maintained through Day 56. Treatment-emergent adverse events were reported in six (75%), seven (100%), and nine (90%) patients with placebo, SPR720 500 mg QD, and SPR720 1000 mg, respectively. Dose-dependent, reversible hepatic enzyme elevations occurred in 11 (65%) patients treated with SPR720, including three (18%) who experienced grade 3 toxicity. Orally administered SPR720 had limited bacteriostatic activity against Mycobacterium avium complex and caused reversible hepatic enzyme elevations in the majority of patients.This study was registered with ClinicalTrials.gov: NCT05496374, 09/08/2022.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.